La vendita allo scoperto per Mixed Martial Arts Group dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Mixed Martial Arts Group. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Mixed Martial Arts Group (AMEX:MMA) Azioni, Report sulle vendite allo scoperto

Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.

Mixed Martial Arts Group Limited Ordinary Shares

Mixed Martial Arts Group Ltd

MEMSCAP SA ORD by Memscap S.A.

META MATERIALS INC by Meta Materials Inc.

Meta Materials Inc

iShares Trust iShares Large Cap Max Buffer Mar ETF

MSM MALAYSIA HOLDINGS BHD by MSM Malaysia Holdings BHD

MSM Malaysia Holdings Bhd

Canaccord Genuity analyst Whitney Ijem maintains Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) with a Buy and raises the price target from $32 to $39.

News

Price Target

Analyst Ratings

VERV

Canaccord Genuity Maintains Buy on Verve Therapeutics, Raises Price Target to $39

Biotech

Events

General

ENTX

Entera Bio Announces EB613 Impact On Both Trabecular And Cortical Bone Compartments With 6 Months Of Treatment In Post-Menopausal Women with Osteoporosis

Macro Economic Events

Econ #s

Economics

UPDATE: USA Import Price Index (MoM) For March -0.1% Vs 0.1% Est.; 0.2% Prior

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5
–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3
–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Data expected for SRP-9003 for LGMD2E/R4 by mid-2025
Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5, 2D/R3, and 2E/R4.
<ul>
<li>SRP-9005 for LGMD type 2C/R5: Following input from the U.S. Food and Drug Administration (FDA), Office of Therapeutic Products (OTP), Sarepta is cleared to proceed with dosing in Study SRP-9005-101 (COMPASS) in the U.S. COMPASS is a first-in-human clinical study of SRP-9005, an investigational gene therapy for LGMD type 2C/R5, or gamma-sarcoglycanopathy.</li>
<li>SRP-9004 for LGMD type 2D/R3: Enrollment and dosing is complete in Study SRP-9004-102 (DISCOVERY).DISCOVERY is a phase 1, proof-of-concept study evaluating safety and expression of the alpha-sarcoglycan protein after treatment with SRP-9004, an investigational gene therapy for the treatment of LGMD type 2D/R3, or alpha-sarcoglycanopathy.</li>
<li>SRP-9003 for LGMD type 2E/R4: Enrollment and dosing is complete in Study SRP-9003-301 (EMERGENE). EMERGENE is a phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec) for the treatment of LGMD type 2E/R4, or beta-sarcoglycanopathy. EMERGENE is a global study and the primary endpoint is the biomarker expression of beta-sarcoglycan protein. A pre-Biologics License Application (BLA) meeting has occurred and the OTP has confirmed eligibility for the accelerated approval pathway for the program. Sarepta remains on track to submit a BLA to the U.S. FDA in the second half of 2025.</li>
</ul>

SRPT

Sarepta Issues Update From Clinical Programs Focused On LGMD Subtypes 2C/R5, 2D/R3, And 2E/R4; FDA Confirmed That Screening, Dosing May Proceed In Study SRP-9005-101 For Lgmd2C/R5

EDISON, N.J.&nbsp;and WARWICKSHIRE, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-jF68eGyeAJ4-c4Yx8ieuCt5Y5AqKQMrTJ35lDPUMYpouEI4BSyKUrNfyV_rUsEsXAHV4UhNSC5blKvKa2YUwbXEQAleALENxQHKOAdfGYYaFeX-bUAR3qNa9D1JG5N3">Eos Energy Enterprises, Inc. (NASDAQ:</a><a href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) ("Eos" or the "Company"), America's leading innovator in designing, manufacturing, and providing zinc-based long duration energy storage systems sourced and manufactured in the United States, today announced it has signed a memorandum of understanding with Frontier Power Ltd. ("Frontier"), a UK-based energy developer, for a 5 GWh energy storage framework agreement. The agreement marks Eos' entrance into a new international market and supports Frontier's plans to submit multiple bids utilizing Eos' Znyth&#x2122;&nbsp;battery technology in the first application window of Ofgem's new long-duration energy storage (LDES) cap and floor scheme.
"We are proud to partner with Frontier Power, a respected leader in UK energy development, to bring Eos' safe and recyclable storage technology to a new market," said Justin Vagnozzi, Senior Vice President of Global Sales at Eos Energy Enterprises. "The novel cap and floor scheme incentivizes investments in long-duration storage technologies that are critical for grid stability and renewable integration. Our participation in this scheme with an established global supply partner like Frontier furthers our commitment to scale our operations, expand our market reach and encourage the adoption of alternative technologies for the energy storage market."
Under the agreement, Eos and Frontier will also look to expand the collaboration globally to new international markets. This partnership also opens the door to developing local manufacturing in the UK. Should significant LDES project volumes materialize using Eos technology, it could incentivize the establishment of manufacturing operations in the UK, supporting domestic supply chains and job creation.
"Our supply chain strategy was designed to be transportable," said Joe Mastrangelo, Eos Chief Executive Officer. "We can co-locate manufacturing capacity near customer demand and not only provide innovative energy storage, but sustainable jobs in regions that have demand for our technology. As that demand grows, both domestically and internationally, we'll expand our manufacturing footprint, and we're excited to partner with Frontier to execute on that vision in the UK market and beyond."
"This agreement reflects Frontier Power's commitment to driving innovation in clean energy while fostering international collaboration," said Humza Malik, Frontier Power Chief Executive Officer. "By working with Eos, we are advancing our portfolio of long-duration storage projects and strengthening trade relations between the US and UK. The prospect of local manufacturing in the UK could further boost economic growth and job creation."

EOSE

Eos Energy and Frontier Power Release 5 GWh Memorandum Of Understanding to Advance Long-Duration Energy Storage In The UK

WIIM

Howmet Aerospace shares are trading lower after Wells Fargo downgraded the stock from Overweight to Equal-Weight and cut its price target from $132 to $118.

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) will release its first-quarter earnings results before the <a href="https://www.benzinga.com/quote/ABT/earnings">opening bell on Wednesday, April 16.</a>
Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, Abbott Laboratories projects quarterly revenue at $10.41 billion, compared to $9.96 billion a year earlier.
On March 10, Bank of America Securities analyst Travis Steed maintained Abbott with a Buy rating and raised the price target from $133 to $150.
With the recent buzz around Abbott Laboratories, some investors may be eyeing potential gains from the company's dividends. Currently, Abbott offers an annual dividend yield of 1.84%. That&#8217;s a quarterly dividend amount of 59 cents per share ($2.36 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $325,274 or around 2,542 shares. For a more modest $100 per month or $1,200 per year, you would need $65,004 or around 508 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.36 in this case). So, $6,000 / $2.36 = 2,542 ($500 per month), and $1,200 / $2.36 = 508 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
ABT Price Action: Shares of Abbott Laboratories gained 0.9% to close at $127.96 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings

<a href="https://www.globenewswire.com/Tracker?data=NaJ1mXAnIHQYhW9xvUpadRWdW6tO4BqMLeYGI1H03USOkjsA5g5B43W4ZZqL-UvrQGkFPaFGuewIE52T_sT05-W5fwA9LHlB0MVRLCrBKq0hEYGTl7f3GnnRZyF_GBt6">KULR Technology Group, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) (the "Company" or "KULR"), a leader in advanced energy management platforms, today announced the launch of a new strategic partnership with <a href="https://www.globenewswire.com/Tracker?data=YTifVer61Wd18jvtBOamLNk0v05zEIAraZWWft6ff6wrmVCTVAXp_29Xt7QDGCJJhmct0ZTcNj1JQEFieUXBU9bLSosNlPfQYDKF_NJQiyo=">German Bionic</a> ("GB"), a leading global robotics company known for its groundbreaking robotic exoskeleton, Apogee ULTRA, to expand into the rapidly growing fields of robotics and artificial intelligence. GB counts global logistics companies, large retailers, hospitals, and major international airports among its customers, including Dachser Intelligent Logistics, GXO, Nuremberg Airport, Canadian Tire, the British consumer electronics retailer Currys, and the Charité Hospital Berlin. According to <a href="https://www.globenewswire.com/Tracker?data=Sz7a9lApF7trAg3QmJqpTQ8osOqXWL35LaXqAULJzYJoVUtRMT3lyigva8BQKaZPftCamC_9frXdRwqhVJ-EGsy23tC5AhAVkPhvrIBY_J_Zessi1bndcBrcx55e4xOrjkd5fS38ZmYgyAq2kzwGIgjTHL_scog_gXrOgO0TVXaYGtEVM5B00uBnwctOE2XWfWBz96aF5CK_PtYJPJVoWe5eXwqve4oSD209zFbtuDBY1m9-5r21R7uFvmJE80NfJvkLKRvKdiHfuoNqyLXF1T8YA8f5TiddMY90HvEgX00=">Spherical Insights</a>, the global wearable robotic exoskeleton market size is expected to reach $41.5 billion by 2033.

KULR

KULR Technology Announces The Launch Of A New Strategic Partnership With German Bionic To Expand Into The Rapidly Growing Fields Of Robotics And AI

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=WG6Pe9bkVVlmXL0avNlHxQDObV9QFLOdfQ2a0Hn-UAntOy7ZmvXkZG_UcDmptza12ztWHIHqmbzNeo4x79G5ENmUV5CAqWDYxv7KqN9IV3U=">Vivani Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and <a href="https://www.globenewswire.com/Tracker?data=CP3tBS-9zcuUzrYIEDAtigpdY9uIKNOXtmXr0ymU1NwpnmLVP3eU2erY1fQX9SLTN2eGQ_aPidEk57pyiyYoxke-FKnJRbOyLtdJmHhqzw8=">Okava Pharmaceuticals, Inc.</a> ("Okava"), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions. Vivani and Okava initiated their collaboration in 2019, with a focus on developing OKV-119 for cardiometabolic conditions in cats.
OKV-119 leverages Vivani's proprietary NanoPortal&#x2122; technology, which provides smooth and steady delivery of therapeutic molecules, including GLP-1 receptor agonists, over extended periods from a single implant. According to Okava, dosing every six months or longer supports a "One-and-Done" approach between office visits consistent with the product profile of Vivani's NPM-115, an ultra long-acting GLP-1 implant in clinical stage development to improve medication adherence and tolerability for the treatment of chronic weight management in humans.
"Caloric restriction, or fasting, is one of the most well-established interventions for extending the lifespan and improving metabolic health in dogs," said Okava CEO Michael Klotsman, PhD, MBA. "But it is also one of the hardest to maintain. OKV-119 mimics many of the physiological effects of fasting—improved insulin sensitivity, reduced fat mass and more efficient energy metabolism—without requiring significant changes in feeding routines or disrupting the human-animal bond that often centers around food."
Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic disease, metabolic decline and shortened lifespans. Similar to the changes humans face as they grow older, aging dogs experience declines in metabolic fitness, leading to weight gain, insulin resistance and loss of muscle mass. Research shows that leaner dogs can live more than two years longer than their heavier counterparts. By restoring and maintaining a healthy metabolism through a single, long-acting dose, OKV-119 has the potential to enhance quality of life, promote healthy aging and become the most impactful life-extending therapy available for dogs.
"This collaboration aligns with Vivani's broader mission to develop innovative medicines that will revolutionize the treatment of chronic diseases by leveraging proprietary drug delivery technologies," said Vivani CEO Adam Mendelsohn, PhD. "This expanded partnership with Okava reflects our shared confidence in the potential of NanoPortal technology to serve a broad array of prospective beneficiaries in the management of metabolic disease. The structure of this expanded partnership minimizes costs and risks for Vivani while integrating upside potential for Vivani shareholders through future milestone payments and royalties. Together with Okava, we are broadening the reach of our technology, meeting unmet needs in veterinary medicine while positioning Vivani to capture future value within an industry segment experiencing continued and unprecedented growth."&nbsp;&nbsp;

Contracts

VANI

Vivani Medical Expands Collaboration With Okava Pharmaceuticals To Include Dogs In Development Of OKV-119, A Long-Acting Glp-1 Therapy For Weight Management, Diabetes and Other Cardiometabolic Conditions

The <a href="https://www.benzinga.com/media/25/03/44163030/chatgpt-parent-openais-specialized-ai-agents-could-cost-up-to-20-thousand-per-month-report">integration of AI agents</a> into blockchain technology will significantly influence the next generation of on-chain ecosystems, according to Pedro Gomes, Founder of WalletConnect.
Speaking with Benzinga, Gomes described a future where intelligent software agents autonomously navigate decentralized applications (dApps), manage digital portfolios and even participate in governance.
Gomes highlighted the transformative potential of AI in the crypto space, particularly through AI agents as autonomous entities that can interact with dApps, execute transactions and make decisions based on real-time data.
"The next generation of the onchain ecosystem will undoubtedly be shaped by AI," he stated, emphasizing their role in enhancing efficiency and user experience. 
He explained that AI agents could manage portfolios, optimize trades, and handle governance tasks like proposing protocol upgrades or adjusting gas fees dynamically. 
"An AI agent could interact with DeFi protocols to manage investments, or with NFT marketplaces to predict and suggest assets," Gomes noted, pointing out how this integration could make Web3 interactions more intuitive and seamless for users.
The complexity of building Web3 infrastructure was a key focus of the discussion. Gomes described the challenge of supporting a diverse ecosystem, from non-custodial wallets to DeFi apps and NFT marketplaces, requiring a protocol that is both robust and adaptable. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44770031/will-a-fed-pivot-rekindle-the-bitcoin-bull-run-if-yes-expect-a-shift-in-institutional-sentiment-experts-say">Will A Fed Pivot Rekindle The Bitcoin Bull Run? If Yes, Expect A &#8216;Shift In Institutional Sentiment,&#8217; Experts Say</a>
He emphasized the importance of staying connected with integrating projects to ensure high standards of user experience (UX), noting, "If users have a bad experience connecting their wallet or completing a transaction, everyone loses." 
To address UX challenges, WalletConnect is developing Smart Sessions, which allow users to pre-approve actions, reducing repetitive signing prompts and bringing dApp interactions closer to Web2's seamless standards.
Gomes also addressed the evolving role of wallets in digital identity frameworks, agreeing with Reown CEO Jess Houlgrave that wallets are becoming "digital filing cabinets for our lives." 
By 2030, he envisions wallets managing not just assets but also medical records, credentials, and access rights, with connectivity protocols like WalletConnect acting as bridges between identity layers and applications. 
On regulatory challenges, Gomes highlighted WalletConnect's collaboration with partners like Reown, whose Travel Rule for Bitcoin exemplifies balancing compliance with decentralization, ensuring the protocol remains legally sound while adhering to its open-source vision.
Mainstream adoption of dApps remains hindered by onboarding difficulties, poor UX and cultural misalignment, according to Gomes.
He pointed to the complexity of setting up wallets and managing keys as significant barriers, alongside the need for more intuitive designs that don't overwhelm users with technical jargon like gas fees. 
He cited Polymarket's success in tapping into mainstream culture through betting and prediction markets as a model for broader resonance, stressing that crypto apps must meet users where they are to achieve widespread adoption.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44763111/bitcoin-stablecoins-will-gain-from-trade-war-experts-say-the-map-is-being-redrawn">Bitcoin, Stablecoins Will Gain From Trade War, Experts Say: &#8216;The Map Is Being Redrawn&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Why 'The Next Generation Of On-Chain Will Be Shaped By AI', According To WalletConnect's Pedro Gomes

TIVC

Tivic Health shares are trading higher after the company expanded its licensing agreement with Statera Biopharma to include worldwide rights for advancing Entolimod as a treatment for neutropenia.

As of April 15, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Certara Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>)</h3>
<ul>
<li>On April 14, Certara issued a year-over-year increase in its first-quarter revenue guidance and announced a $100 million share repurchase program. Additionally, the company announced it launched a non-animal navigator solution to help drug developers reduce reliance on animal testing. The company's stock jumped around 50% over the past five days and has a 52-week high of $17.94.</li>
<li>RSI Value: 80.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CERT Price Action: Shares of Certara gained 11.5% to close at $14.40 on Monday.</li>
<li>Edge Stock Ratings: 25.78 Momentum score with Value at 6.21.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/cert"><img loading="lazy" decoding="async" width="476" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15054617/image-108.png" alt="" class="wp-image-871812" style="width:278px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15054617/image-108.png 476w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15054617/image-108-300x115.png 300w" sizes="(max-width: 476px) 100vw, 476px" /></a></figure>
<h3 class="wp-block-heading">Summit Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)</h3>
<ul>
<li>On March 26, Citigroup analyst Yigal Nochomovitz upgraded Summit Therapeutics from Neutral to Buy and raised the price target from $23 to $35. The company's stock gained around 45% over the past five days and <a href="https://www.benzinga.com/quote/SMMT">has a 52-week high</a> of $33.89.</li>
<li>RSI Value: 74.6</li>
<li>SMMT Price Action: Shares of Summit Therapeutics gained 12.4% to close at $26.13 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Third Harmonic Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>)</h3>
<ul>
<li>On April 14, Third Harmonic announced that its board approved and adopted a plan for the liquidation and dissolution of the company and the distribution of remaining cash to shareholders, including any proceeds from asset and intellectual property sales. "Our management team and board of directors together have completed an efficient review of our strategic alternatives for maximizing the value of our assets and have determined that returning cash to shareholders and selling our assets, including THB335, is the best path forward," said Natalie Holles, CEO of Third Harmonic Bio. The company's stock gained around 46% over the past month and has a<a href="https://www.benzinga.com/quote/THRD"> 52-week high</a> of $16.94.</li>
<li>RSI Value: 87.7</li>
<li>THRD Price Action: Shares of Third Harmonic Bio gained 39.8% to close at $5.09 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

CERT

SMMT

THRD

Top 3 Health Care Stocks You May Want To Dump This Quarter

Evercore ISI Group analyst Amit Daryanani maintains Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Outperform and lowers the price target from $130 to $100.

ANET

Evercore ISI Group Maintains Outperform on Arista Networks, Lowers Price Target to $100

United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/UAL/earnings">closing bell on Tuesday, April 15.</a>
Analysts expect the Chicago, Illinois-based company to report quarterly earnings at 74 cents per share, versus a year-ago loss of 15 cents per share. United Airlines projects to report quarterly revenue at $13.18 billion, compared to $12.54 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
United, last month, said it has begun construction on a 140,000-square-foot Ground Service Equipment (GSE) Maintenance Facility and unveiled a Technical Operations Training Center at George Bush Intercontinental Airport (IAH).
United Airlines shares gained 0.1% to close at $65.69 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/UAL/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Brandon Oglenski maintained an Overweight rating and cut the price target from $140 to $94 on April 8, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Susquehanna analyst Christopher Stathoulopoulos maintained a Positive rating and cut the price target from $130 to $90 on April 7, 2025. This analyst has an accuracy rate of 72%.</li>
<li>UBS analyst Thomas Wadewitz downgraded the stock from Buy to Neutral and slashed the price target from 107 to $59 on April 7, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Raymond James analyst Savanthi Syth downgraded the stock from Outperform to Market Perform on April 2, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Jefferies analyst Sheila Kahyaoglu maintained a Buy rating and slashed the price target from $154 to $80 on April 1, 2025. This analyst has an accuracy rate of 71%.</li>
</ul>
Considering buying UAL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/bc72dcb8-e0b1-4146-9da3-d92701246c37" alt="" style="width:496px;height:auto" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Top Wall Street Forecasters Revamp United Airlines Price Expectations Ahead Of Q1 Earnings

MURA

Mural Oncology shares are trading higher after the company announced plans to explore strategic alternatives and discontinue clinical development of nemvaleukin.

Tivic Health Extends Worldwide License Of TLR5 Agonist Entolimod To Include Treatment Of Neutropenia

NEW YORK and TOKYO and TAIPEI, April 15, 2025 /PRNewswire/ -- TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>), Asia's next-generation digital media and data group, today announced a strategic partnership with one of Taiwan's leading e-commerce brands, PChome Online (Stock Code: 8044-TW). This collaboration marks a significant step in shifting the retail media ecosystem by integrating the DNA of Content Marketing and Affiliate Marketing to launch an innovative Content Commerce operation methodology. Using high-quality content to directly drive conversion, this approach will actively promote products across various industry sectors on PChome.

TNMG

TNL Mediagene Announces Strategic Partnership With Taiwan's PChome Online To Launch Content Commerce Operation Methodology

Evercore ISI Group analyst Durgesh Chopra downgrades Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) from Outperform to In-Line and raises the price target from $46 to $48.

Downgrades

Evercore ISI Group Downgrades Exelon to In-Line, Raises Price Target to $48

<ul>
<li>Analysis of blood samples from patients treated with&nbsp;Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug.</li>
<li>The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis.
<ul>
<li>Data also show a significant decrease in ANP (Atrial Natriuretic Peptide), a clinically validated marker for heart failure. &nbsp;</li>
</ul>
</li>
</ul>

GLMD

Galmed Unveils Pharmacodynamic Blood Markers For Aramchol

Press Releases

BJJLink Fuels MMA.inc's Vision to Transform Mixedmartialarts.com into the Global Epicenter for Martial Arts targeting an $18 billion industry

Mixed Martial Arts Group Limited Publishes Annual Report and Form 20-F for Fiscal Year 2024.

MMA.inc Co-Founder John Kavanagh and Investor Conor McGregor Join President Trump's Inauguration as MMA Takes Center Stage

MMA.inc Acquisition of BJJLink Helps Fuel +40% YOY* Revenue Growth On The Platform As It Targets 44,000 Gyms In An $18.6bn Martial Arts Industry in the US

MMA.inc on Track to Achieve US$0.75 Million1 in Warrior Training Program Gross Sales for the March 25 Quarter, Driven by Record-Breaking 200% YoY Growth2

Mixed Martial Arts (MMA) Market is Substantially Growing, Morphing into a Billion Dollar Opportunity

MMA.inc Unveils Fully Integrated Community and Commerce Platform for the $18.6 Billion Martial Arts Industry

MMA.INC to Expand Reach Across 1,000+ Gyms Coaches and Participants in New Partnership with New Zealand Brazilian Jiu-Jitsu Federation

MMA.INC Expands Further into Latin America with BJJLink Capitalizing on Growth of Brazilian Jiu-Jitsu: $15 Million Annual Revenue Opportunity*

Mixed Martial Arts Group Limited Secures $2 Million Non-Dilutive Financing

PTON

SPHR

Allurion Technologies

The Beachbody Company, Inc. Class A Common Stock

Beachbody Co

Carriage Servs

E-Home Household Service Holdings Limited - Ordinary shares

E-Home Household Service

European Wax Center, Inc. - Class A Common Stock

European Wax Center

Frontdoor

H&R Block

Mister Car Wash

Mixed Martial Arts Group

MEDIROM Healthcare Technologies Inc. - American Depositary Share

MEDIROM Healthcare Techs

OneSpaWorld Holdings Limited - Common Shares

OneSpaWorld Hldgs

Wag Group

Regis

Service Corporation International Common Stock

Service Corp Intl

SunCar Technology Group Inc. - Ordinary Shares

SunCar Tech Gr

WW International

XWELL

YSX Tech. Co., Ltd - Class A Ordinary Shares

Comments

Mixed Martial Arts Group

Vendite allo scoperto

Mixed Martial Arts Group (AMEX:MMA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO